source
- Revolution Medicines' Rasonque generates $198 million in sales within five weeks of U.S. approvalRevolution Medicines reported that its pancreatic cancer therapy Rasonque has achieved $198 million in revenue in the first five weeks after receiving U.S. approval. The company said more than 5,00…
- Medicare to slash 340B drug payments and expand site-neutral rules in 2027Medicare finalized a rule that will cut payments for drugs covered by the 340B discount program and broaden site-neutral payment policies beginning in 2027. The rule is expected to reduce Medicare…